Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Pharvaris N.V. (NASDAQ:PHVS) has been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $49.1818.

A number of equities analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Citizens Jmp cut their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. UBS Group set a $74.00 price target on shares of Pharvaris in a research report on Wednesday, May 13th. Finally, Wolfe Research began coverage on Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company.

Pharvaris Price Performance

Shares of PHVS stock opened at $29.88 on Wednesday. Pharvaris has a 12 month low of $15.46 and a 12 month high of $33.33. The firm has a market capitalization of $1.95 billion, a P/E ratio of -9.40 and a beta of -2.34. The company’s fifty day moving average price is $28.61 and its two-hundred day moving average price is $26.96.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. On average, sell-side analysts anticipate that Pharvaris will post -3.25 EPS for the current year.

Insider Transactions at Pharvaris

In related news, Director Viviane Monges sold 9,667 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $30.29, for a total value of $292,813.43. Following the completion of the sale, the director directly owned 5,500 shares of the company’s stock, valued at $166,595. The trade was a 63.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $29.22, for a total value of $66,972.24. Following the completion of the sale, the chief executive officer directly owned 137,500 shares of the company’s stock, valued at approximately $4,017,750. This represents a 1.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 209,948 shares of company stock valued at $6,268,141 over the last 90 days. Corporate insiders own 11.84% of the company’s stock.

Institutional Trading of Pharvaris

Several hedge funds and other institutional investors have recently bought and sold shares of PHVS. Wellington Management Group LLP bought a new stake in Pharvaris in the third quarter valued at about $43,282,000. Paradigm Biocapital Advisors LP increased its holdings in Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after buying an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in Pharvaris in the third quarter valued at about $15,613,000. Commodore Capital LP increased its holdings in Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after buying an additional 507,043 shares during the last quarter. Finally, General Atlantic L.P. increased its holdings in Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after buying an additional 500,000 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.